Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluad Quadrivalent Immunogenicity and Safety in Adults 50-64
NCT05044195Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in influenza, sponsored by CSL Seqirus. Started Sep 2021; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05044195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044195.